450950.Kq
The company designs, develops, and sells medical equipment and technology, primarily focused on diagnostic imaging and treatment solutions for healthcare providers.
Business. The company designs, develops, and sells medical equipment and technology, primarily focused on diagnostic imaging and treatment solutions for healthcare providers.
Analyst recommendations
4 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company designs, develops, and sells medical equipment and technology, primarily focused on diagnostic imaging and treatment solutions for healthcare providers.
The company maintains a strong liquidity position, with a current ratio of 8.77 and a cash and equivalents balance of 6,904.3 million KRW, indicating a robust ability to meet short-term obligations. The debt-to-equity ratio is low at 0.04, suggesting minimal leverage and a conservative capital structure. The price-to-book ratio of 7.65 and a market cap of 357.8 billion KRW reflect a premium valuation relative to its book value.
Profitability metrics show a return on equity (ROE) of 19.7% and a return on assets (ROA) of 17.64%, both significantly above the industry median for Advanced Medical Equipment & Technology. The company's operating margin is 27.4% (calculated from operating income of 10.4 billion KRW on revenue of 37.9 billion KRW), which is a strong indicator of operational efficiency. The gross margin of 79.2% (calculated from gross profit of 30.0 billion KRW) also reflects a high level of cost control and pricing power.
The company operates as a single business segment, with no disclosed geographic revenue breakdown. This lack of diversification may expose the company to regional economic or regulatory risks, though the absence of a geographic breakdown makes it difficult to assess the extent of such exposure.
The company's revenue growth is expected to remain stable, with no significant changes in the current fiscal year or the next. The company's free cash flow of 6.4 billion KRW and operating cash flow of 4.99 billion KRW support its ability to fund operations and invest in growth opportunities. However, the capital expenditure of -1.5 billion KRW suggests a reduction in investment in new projects or equipment.
The company's risk profile is low, with no immediate liquidity or dilution flags detected. The low dilution risk is supported by the fact that the number of basic and diluted shares outstanding is the same, indicating no near-term threat from share issuance. The company's conservative capital structure and strong cash position further reduce financial risk.
Recent analyst estimates suggest a positive outlook, with a mean price target of 15,000 KRW and a median price target of 15,000 KRW. The mean recommendation of 1.25 (on a scale of 1 to 5) indicates a strong buy consensus among analysts. The company has not disclosed any recent filings or transcripts that would suggest material changes in its business operations or strategy.
- The company has a strong liquidity position with a current ratio of 8.77 and a low debt-to-equity ratio of 0.04.
- Profitability metrics, including ROE of 19.7% and ROA of 17.64%, are well above industry medians.
- The company's valuation is premium, with a price-to-book ratio of 7.65 and a market cap of 357.8 billion KRW.
- Analysts have a positive outlook, with a mean price target of 15,000 KRW and a strong buy consensus.
- The company's lack of geographic revenue diversification may pose regional risk, though the extent is unclear.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 511,83 |
| Revenue | —no estimate | —no estimate | 59,3B KRW |
| Operating income | —no estimate | —no estimate | 22,6B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 450950.KQ Market data — financials · 2026-05-26
- Asterasys Co Ltd Market data — analyst estimates · 2026-05-26